

Valneva SE

Notice

The following data represent a snapshot taken at the time of the initial public offering / new listing / inclusion in the MTF and are not updated regularly.

ISIN:	FR0004056851	
Symbol:	VLA	
Trading segment:	Second Regulated Market	
Market segment:	prime market	
Category:	par value bearer shares	
Number of shares:	up to 39,332,581 common shares	
Share capital:	up to EUR 5,899,887.15	
First day of trading:	scheduled for May 28, 2013	
Offered shares:	-	
Offering period:	-	
Price fixing:	-	
Price range:	-	
Offer price:	-	
Issuing volume:	-	
Listing Agent:	Erste Group Bank AG	
Shareholder structure:	Grimaud Group	27.67 %
	La Financière Grand Champ	0.71 %
	Individual shareholders from Grimaud Family	0.92 %
	Novartis	6.80 %
	Members of the management board and employees	2.64 %
	Freefloat	61.26 %
Address:	La Corbière 49450 Roussay France	
Internet:	www.valneva.com	
Company profile:	<i>(Profile provided by the company)</i>	

Valneva SE

Valneva is a new European biotech company focusing on vaccines and antibodies, striving to become a leader in its field.

It was created in 2013 through the merger in between Intercell AG and Vivalis SA, complementing the two value propositions – antibody discovery and vaccines development and commercialization.

Valneva's mission is to use the power of innovation to excel in both antibody discovery and vaccines development and commercialization, either in-house or in collaboration with industrial partners. Valneva generates revenue from diversified sources from both its marketed product and current and new commercial partnerships.

It has a portfolio of product candidates (in-house/partnered) and technology platforms that are becoming widely adopted by the biopharmaceutical industry at large.

The internationally experienced management team has a proven track-record and is focused on research, development, manufacturing, and commercialization according to the business's mission.